TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration
TFF Pharmaceuticals (NASDAQ: TFFP) has announced its intention to voluntarily delist its common stock from the Nasdaq Capital Market. The company plans to file Form 25 with the SEC and Nasdaq around February 16, 2025, with the delisting becoming effective 10 days after filing. TFF has not made arrangements for listing or quoting its common stock on any other exchange or market. This delisting action is part of the company's planned liquidation and dissolution process.
TFF Pharmaceuticals (NASDAQ: TFFP) ha annunciato la sua intenzione di dismettere volontariamente le proprie azioni ordinarie dal Nasdaq Capital Market. L'azienda prevede di presentare il Modulo 25 alla SEC e al Nasdaq intorno al 16 febbraio 2025, con la dismissione che diventerà efficace 10 giorni dopo la presentazione. TFF non ha effettuato organizzazioni per la quotazione o la negoziazione delle proprie azioni ordinarie su alcun altro mercato o borsa. Questa azione di dismissione fa parte del piano dell'azienda per il processo di liquidazione e scioglimento.
TFF Pharmaceuticals (NASDAQ: TFFP) ha anunciado su intención de abandonar voluntariamente sus acciones ordinarias del Nasdaq Capital Market. La compañía planea presentar el Formulario 25 ante la SEC y el Nasdaq alrededor del 16 de febrero de 2025, siendo efectiva la deslisting 10 días después de la presentación. TFF no ha hecho arreglos para la cotización o negociación de sus acciones ordinarias en ninguna otra bolsa o mercado. Esta acción de deslistado es parte del proceso planeado de liquidación y disolución de la empresa.
TFF Pharmaceuticals (NASDAQ: TFFP)는 Nasdaq Capital Market에서 자사의 보통주를 자발적으로 상장 폐지할 계획이라고 발표했습니다. 회사는 2025년 2월 16일경에 SEC와 Nasdaq에 Form 25를 제출할 예정이며, 상장 폐지는 제출 후 10일 후에 시행됩니다. TFF는 다른 거래소나 시장에서 보통주의 상장 또는 인용을 위한 준비를 하지 않았습니다. 이 상장 폐지 조치는 회사의 예정된 청산 및 해산 프로세스의 일환입니다.
TFF Pharmaceuticals (NASDAQ: TFFP) a annoncé son intention de retirer volontairement ses actions ordinaires du Nasdaq Capital Market. La société prévoit de déposer le formulaire 25 auprès de la SEC et du Nasdaq vers le 16 février 2025, le retrait devenant effectif 10 jours après le dépôt. TFF n'a pas pris de dispositions pour la cotation ou le négoce de ses actions ordinaires sur d'autres bourses ou marchés. Cette action de retrait fait partie du processus de liquidation et de dissolution prévu par l'entreprise.
TFF Pharmaceuticals (NASDAQ: TFFP) hat die Absicht angekündigt, ihre Stammaktien freiwillig vom Nasdaq Capital Market abzubestellen. Das Unternehmen plant, etwa am 16. Februar 2025 das Formular 25 bei der SEC und Nasdaq einzureichen, wobei die Abbestellung 10 Tage nach der Einreichung wirksam wird. TFF hat keine Vorkehrungen für die Börsennotierung oder den Handel seiner Stammaktien an einer anderen Börse oder einem anderen Markt getroffen. Diese Abbestellmaßnahme ist Teil des geplanten Liquidations- und Auflösungsprozesses des Unternehmens.
- None.
- Voluntary delisting from Nasdaq Capital Market
- No alternative trading arrangements made for common stock
- Company planning complete liquidation and dissolution
- Loss of major market access for shareholders
Insights
The announcement of TFF Pharmaceuticals' voluntary delisting from Nasdaq, coupled with plans for liquidation and dissolution, signals a terminal event for the company. This development carries severe implications for all stakeholders, particularly shareholders. The absence of arrangements for alternative trading venues is particularly concerning, as it typically results in shares becoming essentially worthless once delisting occurs.
The timing of events is important to understand: the Form 25 filing expected around February 16, followed by a 10-day waiting period before delisting becomes effective. During this period, shareholders should be aware that trading volumes might decrease significantly, potentially leading to reduced liquidity and increased price volatility. The subsequent liquidation process typically involves:
- Appointment of a liquidation trustee
- Sale of remaining assets
- Settlement of outstanding debts and liabilities
- Distribution of any remaining proceeds to shareholders (if any)
For the broader biotech sector, this event serves as a stark reminder of the inherent risks in development-stage pharmaceutical companies. The liquidation process could extend several months or even years, during which shareholders maintain certain rights but face significant uncertainty regarding any potential recovery of their investment.
FOXBOROUGH, Mass., Feb. 6, 2025 /PRNewswire/ -- TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) today announced that the Company has provided notification to The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to voluntarily delist the Company's common stock, par value
The withdrawal of the Common Stock from listing and registration is being undertaken in connection with the planned the liquidation and dissolution of the Company.
Forward Looking Statements
Statements made in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding our plans to wind down our operations or other statements not of historical fact. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: the timing, progress and results of our planned wind down; general market conditions; and other risks described in TFF Pharmaceuticals' filings with the Securities and Exchange Commission under the heading "Risk Factors". All forward‐looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. TFF Pharmaceuticals undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law.
View original content:https://www.prnewswire.com/news-releases/tff-pharmaceuticals-announces-delisting-from-nasdaq-and-potential-sec-deregistration-302370494.html
SOURCE TFF Pharmaceuticals
FAQ
When will TFFP stock be delisted from Nasdaq?
Will TFFP stock be traded on other exchanges after Nasdaq delisting?
Why is TFFP delisting from Nasdaq?
What happens to TFFP shareholders after the Nasdaq delisting?
